Results 1 to 10 of about 50,600 (264)
Journal of Cachexia, Sarcopenia and Muscle, 2018 Background Cachexia is a multifactorial syndrome that is highly prevalent in advanced cancer patients and leads to progressive functional impairments. The classification of cachexia stages is essential for diagnosing and treating cachexia. However, there
Zhou Ting, Bangyan Wang, Shiying Yu
exaly +2 more sources
JCSM Rapid Communications, 2022 Background Cancer patients who exhibit cachexia lose weight and have low treatment tolerance and poor outcomes compared with cancer patients without weight loss.
Jeffery M. Chakedis +7 more
doaj +1 more source
Journal of Cachexia, Sarcopenia and Muscle, 2021 Background Disuse decreases muscle size and is predictive of mortality across multiple pathologies. Detriments to mitochondrial function are hypothesized to underlie disuse‐induced muscle atrophy.
Megan E. Rosa‐Caldwell +9 more
doaj +1 more source
QJM: An International Journal of Medicine, 2005 Cancer cachexia is a severe debilitating disorder for which there are currently few therapeutic options. It is driven by the release of pro-inflammatory cytokines and cachectic factors by both host and tumour. Over the past few years, basic science advances have begun to reveal the breadth and complexity of the immunological mechanisms involved, and in
J N, Gordon, S R, Green, P M, Goggin
openaire +2 more sources
Journal of Cachexia, Sarcopenia and Muscle, 2021 Background Muscle atrophy is a common pathology associated with disuse, such as prolonged bed rest or spaceflight, and is associated with detrimental health outcomes.
Megan E. Rosa‐Caldwell +10 more
doaj +1 more source
Screening Assessment and Therapy Intervention of Cancer Cachexia in Adult Patients——Based on the Interpretation of Cancer Cachexia in Adult Patients: ESMO Clinical Practice Guidelines [PDF]
Zhongguo quanke yixue, 2023 Cancer cachexia is a cancer-related, multi-factorial, irreversible clinical syndrome characterized by progressive nutritional consumption, which greatly reduces the survival expectation and quality of life of cancer patient.
WANG Rui, WANG Xiaomei, PENG Guoqing, YU Huan, WANG Sihan, XIA Jin
doaj +1 more source
European Heart Journal Supplements, 2019 AbstractCachexia is a multifactorial disease characterized by a pathologic shift of metabolism towards a more catabolic state. It frequently occurs in patients with chronic diseases such as chronic heart failure and is especially common in the elderly. In patients at risk, cardiac cachexia is found in about 10% of heart failure patients.
Lena, Alessia +2 more
openaire +3 more sources
Journal of Cachexia, Sarcopenia and Muscle, 2010 Ghrelin, a natural ligand for the growth hormone (GH)‐secretagogue receptor, is primarily produced in the stomach. Administration of ghrelin stimulates food intake and GH secretion in both animals and humans. Ghrelin is the only circulating hormone known to stimulate appetite in humans.
Akamizu, Takashi, Kangawa, Kenji
openaire +2 more sources
Cachexia in Cancer Patients: Systematic Literature Review
Asian Journal of Oncology, 2020 Introduction Cachexia in cancer patients, especially in advanced stage, is recently known as an emerging problem. Cachexia occurs in about half of all patients with neoplastic disease.
Timotius I. Hariyanto, Andree Kurniawan
doaj +1 more source
Cancer Medicine, 2023 Background The presence of cachexia negatively impacts the prognosis of patients with cancer. However, the mechanisms behind the development of cachexia and its prognostic impact on immunotherapy efficacy are not fully understood.
Daiki Murata +8 more
doaj +1 more source